{
  "ptid_time": "067_S_4767_2012-06-11",
  "img_path": "/data/qiuhui/data/adni/images/067_S_4767/2012-06-11/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 54,978 mm³, 146.1% above the reference mean. With a Z-score of 3.66 (100.0th percentile), this represents profound enlargement; hippocampal volume measures 6,107 mm³, 20.5% below the reference mean. With a Z-score of -2.30 (1.1th percentile), this represents significant atrophy; whole brain volume measures 925,027 mm³, 10.1% below the reference mean. With a Z-score of -1.26 (10.4th percentile), this represents mild atrophy; entorhinal cortex volume measures 2,970 mm³, 23.7% below the reference mean. With a Z-score of -1.84 (3.3th percentile), this represents moderate atrophy; fusiform gyrus volume measures 17,324 mm³, 4.9% below the reference mean. With a Z-score of -0.55 (29.2th percentile), this represents normal volume ; middle temporal gyrus volume measures 18,995 mm³, 7.4% below the reference mean. With a Z-score of -0.66 (25.5th percentile), this represents normal volume . ",
  "text_data": "Age is 66.4 years. Gender is Female. Education: 18 years. Handedness: Right. Race: White. Medical history: Psychiatric; Neurologic; Cardiovascular; Dermatologic-Connective Tissue; Endocrine-Metabolic; Gastrointestinal; Allergies or Drug Sensitivities; Alcohol Abuse; Smoking. MMSE: 30.0. MoCA: 26.0. Logical Memory: 8.0. APOEε4 alleles: 1.0. Biomarker levels: Florbetapir (AV45): 1.05 SUVR (normal ); Amyloid beta: 822.10 pg/mL (normal ); Total tau: 171.50 pg/mL (normal ); Phosphorylated tau: 17.02 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant hippocampal and entorhinal cortex atrophy, along with profound ventricular enlargement, which are strong indicators of neurodegeneration. However, cognitive scores (MMSE 30, MoCA 26) are within normal limits, and CSF/AV45 biomarkers are normal, suggesting no current amyloid or tau pathology.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely non-amyloid/non-AD subtype, possibly hippocampal sclerosis or other neurodegenerative etiology).  \n\n**Confidence:** **Medium** (high confidence in neurodegeneration based on structural changes, but unclear etiology due to normal biomarkers and preserved cognition).  \n\n*Note: Given the discrepancy between imaging and cognition, longitudinal follow-up is recommended to assess progression.*",
  "timestamp": "2025-07-26T08:39:57.171541"
}